Trellus Health Plc · LSE:TRLS
Trellus Health — H1 2024 Earnings Presentation
16 slides from Trellus Health's earnings presentation, September 2024
Slide 1: Fostering resilience and better health—while delivering lasting value to the healthcare system
® Fostering resilience and better health—while delivering lasting value to the healthcare system Interim Results for the period ended 30 June 2024 Marla C. Dubinsky, MD Joy Bessenger Co-Founder and CEO Chief Financial Officer
Slide 2: Disclaimer
Disclaimer • The information contained in these slides and the accompanying oral presentation (together, the “Presentation”) has been prepared by Trellus Health plc (the “Company”). The Presentation is subject to updating, completion, revision and amendment without notice and as such it may change m
Slide 3: Company Overview
Company Overview • Trellus Health® delivers a validated, personalized solution for managing chronic conditions, proven to enhance outcomes, improve adherence to medications and treatment plans, and lower the costs associated with complex chronic disease management1. • Leveraging a proprietary resili
Slide 4: Interim 2024 Highlights
Interim 2024 Highlights Signed and launched first commercial-scale pilot with large US Health Plan Signed 2 licensing agreements with pharma for proprietary assessments and content New Board Chair appointed with extensive US health experience-Kevin Murphy Jr Received and maintained SOC2 Type 2 certi
Slide 5: Post Period Highlights
Post Period Highlights Extended enrollment for large health plan beyond initial 6-month enrollment period Brian Griffin, was appointed to the board of directors and brings US healthcare and pharmaceutical sector expertise ® 5 © 2024 Trellus Health Inc. All Rights Reserved
Slide 6: High Level Summary of Large Health Plan Program
High Level Summary of Large Health Plan Program • Launched March 2024 • Region: New York and Connecticut • Initial term 21 months • Slower enrolment than expected with small numbers of enrolled patients to date • Extension of enrolment phase to support enrolment •Rolling enrolment over term of the c
Slide 7: Large Health Plan Interim Program Data
Large Health Plan Interim Program Data • 90% of members choose to join Trellus Elevate after their first virtual visit with our Nurse Navigators • 78% of members reported greater confidence in managing their condition within just 3 months of starting their personalized Trellus Elevate program • Self
Slide 8: Interim Financial Highlights
Interim Financial Highlights • Net cash of $8m as to 30 June 2024 (31 December 2023: $12.2m; H1 2023: $15.8m) • Adjusted EBITDA* loss of $3.6m for period to 30 June 2024 (H1 2023: $5.8m) with revenue of $50k (H1 2023: $14k) • c.$9.4m capital investment to date in technology platform development and
Slide 9: Levers for Growth and Value
Levers for Growth and Value • Focus on High Cost Trellus Elevate Quadrants with highest cost members (high-cost claimants) • High-cost claimants represent 50% of the medical and drug spend in the US; • US Health plan pricing assumed across all four of our quadrants (average of high and low-cost memb
Slide 10: Trellus Elevate Quadrants: Targeted Identification & Risk Stratification
Trellus Elevate Quadrants: Targeted Identification & Risk Stratification Approach for High-Cost Claimant Conditions Trellus Elevate Resilience Score Low High 1 $$$$ 3 $$$ Condition Complexity Score Low Resilience High Resilience High High Medical Spend High Medical Spend Trellus Elevate High Pharmac
Slide 11: Steps to Trellus Elevate Engagement
3 Steps to Trellus Elevate Engagement TOTAL ADDRESSABLE MARKET (TAM) TOTAL ELIGIBLE MEMBERS (TEM) Step 1 Step 2 Step 3 • Start The Online • Complete Virtual • Engage with the Risk Assessment Screening Call Platform © 2024 Trellus Health Inc. All Rights Reserved
Slide 12: Focused on Three Main Verticals
Focused on Three Main Verticals ➢ Each vertical has several paths to meet client’s needs ➢ Low cost to tailor program due to nimble platform and methodology ➢ Consistent messaging to marketplace ➢ Improve patient outcomes, increase medication adherence while lowering overall healthcare costs Value P
Slide 13: Strategy for Expanding Program Access and Growth
Strategy for Expanding Program Access and Growth • Focus on verticals with faster sales cycles • Clinical Trials (early phase > late phase) • Pharma Patient Support Program • Health Plans • Focus on clients with largest IBD Total Eligible Members (TEMs) • Large Health Plan with large number of IBD c
Slide 14: Summary & Outlook
Summary & Outlook • Positive commercial progress with agreement signed with large health plan • Enrolment period extension to support increased uptake • Opportunities for Trellus Elevate across new verticals including pharmaceutical sector • Ongoing commercial discussions across verticals including
Slide 15: Trellus Health Board & Senior Management
Trellus Health Board & Senior Management Marla Dubinsky, MD Kevin L. Murphy, Jr. Joy Bessenger* CEO*, Co-Founder Non-executive Chair Chief Financial Officer Professor, Pediatrics and Medicine Former SVP, Payer Relations & Managed Care, Former Senior Vice President, Finance and Chief of Division of P
Slide 16: UK Office and US Office contact details
UK Office Avon House, 19 Stanwell Road info@trellushealth.com Penarth, Cardiff CF64 2EZ US Office 44 South Broadway, Ste 100 trellushealth.com White Plains, NY 10601, USA ®